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menyangkut sistem layanan kesehatan dan ekonomi kesehatan. 
Metode: Kami melakukan sebuah studi retrospektif terhadap 411 pasien yang mendapat terapi eradikasi 
? pylori lini pertama di ?umah ?akit ?uyoukai ?urakami dari 1 ?ktober ??14 hingga ?1 ?aret ??1?. Kami 
menghitung angka pemantauan lan?utan pada satu tahun pas?a pengobatan terapi eradikasi. ?elain itu? kami 
mengeksklusi ?? pasien yang diketahui se?ara pasti menerima e?aluasi pas?a pengobatan karena diketahui 
melakukan pertemuan untuk pemantauan lan?utan dengan ahli gastroenterologi ?n ? ??? atau kun?ungan ulang 
Volume 19, Number 3, December 2018 149
Study of the Completion of Follow-up After Helicobacter pylori Eradication Therapy
ke dokter lain ?n ? 4?? dan mengikutsertakan ??? pasien dalam populasi studi akhir. Kami menggunakan 
model regresi logistik untuk mengidenti?kasi berbagai faktor rele?an yang berkontribusi pada penyelesaian 
pemantauan pas?a terapi eradikasi.
Hasil: ?ingkat penyelesaian pemantauan pas?a eradikasi adalah ??.?? ???4?411?. ?nalisis multi?ariat 
menun?ukkan bah?a ad?usted odds ratios untuk umur ?? 4? years?? ?enis kelamin ?perempuan?? dan tindakan 
pen?egahan kanker i? ?an?er ?esofagogastroduodenos?opi setelah penapisan radiogra?s untuk kanker lambung 
dan permintaan untuk pemeriksaan infeksi ?. pylori? adalah 1.?? ???? ??? 1.11??.??? p ? ?.???? 1.?? ???? 
??? 1.????.?4? p ? ?.??? and 4.?1 ???? ??? 1.?1?1?.?? p ? ?.?1?? se?ara berturut?turut.
Simpulan: ?ada usia ? 4? tahun? ?enis kelamin perempuan dan tindakan pen?egahan kanker lambung se?ara 
independen berhubungan dengan lebih tingginya angka penyelesaian pemantauan pas?a eradikasi.
Kata kunci: ?eli?oba?ter pylori? eradikasi? follo??up? ?ompletion
INTRODUCTION
?eli?oba?ter pylori infection is associated with 
both peptic ulcers and gastric cancer, and the 
International Agency for Research on Cancer has 
recommended population-based screening and the 
eradication of H. pylori for controlling gastric cancer.1,2 
In Japan, the number of patients receiving H. pylori 
eradication therapy has been increasing rapidly since 
the introduction of gastric cancer screening (ABC 
method) and the recent use of H. pylori eradication 
therapy for chronic gastritis.3 
Vonoprazan (VPZ), a novel oral potassium-
competitive acid blocker, was approved for H. pylori 
eradication by the Japanese health insurance program 
in 2015, and recent studies have shown that VPZ-
?????????????????????????????????????????????H. pylori 
eradication than does a proton pump inhibitor (PPI)-
based triple therapy.4,5 Because no therapeutic regimens 
have an eradication rate of 100%, post-treatment 
evaluation is necessary to ensure that sufficient 
eradication therapy for H. pylori has been provided. 
However, not all patients are evaluated after receiving 
eradication therapy. Although patients without post-
treatment evaluation should be contacted and invited for 
a post-eradication follow-up, the medical staffs might be 
inclined to reduce the load of patient contact. Therefore, 
we investigated the relevant factors contributing to the 
completion of post-eradication follow-up.
METHOD
We performed a retrospective study of 411 patients 
???????????????????????H. pylori eradication therapy 
at Fuyoukai Murakami Hospital in Aomori city from 
October 1, 2014 to March 31, 2016. No patients had 
previously received H. pylori eradication therapy. 
We used esophagogastroduodenoscopy (EGD) to 
confirm the absence of malignancy and a rapid 
urease test to diagnose H. pylori infection. One of 
two gastroenterologists initiated H. pylori eradication 
therapy and used a 13C-urea breath test (UBT) for the 
evaluation of H. pylori eradication. The subjects were 
instructed to visit Fuyoukai Murakami Hospital for a 
post-eradication test at > 2 months after completing 
the therapy and to avoid taking PPIs, VPZ, antibiotics, 
ecabet sodium and polaprezinc within 2 weeks of 
evaluating eradication due to the likelihood of false-
negative results in the UBT.6,7
We calculated the rate of post-treatment follow-
up at 1 year after completing the eradication therapy. 
??? ????????????? ???????????????????????????????????
received post-treatment evaluation because of 
follow-up appointments with gastroenterologists 
(n = 29) or return visits to other physicians (n = 47) 
????????????????????????????????????????????????????????
We used logistic regression models for identifying the 
relevant factors that contributed to the completion of post-
eradication follow-up and sequentially introduced six 
?????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
of dyspepsia and preventive measures for gastric cancer 
(EGD after radiographic screening for gastric cancer and 
a desire for the diagnosis of H. pylori infection)—into the 
model. The abovementioned cut-off value for age at the 
completion of post-eradication evaluation was obtained 
?????????? ?????????????????????????????????????????????
= 60.9%) in the receiver operating characteristic curve 
??????????????????????????????????????????????????????
interval (CI): 0.528–0.668].
The present study was approved by the institutional 
ethics committee, and informed consent was obtained 
from the patients. We conducted all statistical analyses 
????????????????????????????????????????????????????
???????????????????????????????8
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RESULTS
The rate of completion of follow-up after H. pylori 
eradication therapy was 78.8% (324/411). The patients’ 
??????????????????? ??????????????????????????????????
Table 1. The median age was 48 years; the median ages 
of those in complete and incomplete groups were 50 
years (range, 14–76 years) and 44 years (range, 21–79 
years), respectively.
Multivariate analysis revealed that the adjusted 
??????????????????????????????????????????????????????
preventive measures for gastric cancer were 1.85 (95% 
??????????????????????????????? ????????????????????
?????????? ????????? ????????? ??????????? ???????????
respectively (Table 2).
DISCUSSION
In the present study, the rate of patients who 
underwent a post-treatment examination to determine 
???????????????H. pylori eradication therapy was 33% 
higher than the value (45.7%; 48/105) reported in a 
Danish study; however, the patients’ backgrounds 
differed between the two studies.9 Furthermore, a 
Canadian study reported that patients who had a formal 
follow-up appointment were more likely to complete 
the therapy [96.3% (77/80) vs. 50.0% (11/22)].10 In the 
present study, all 29 patients who were excluded from 
?????????????????????????????????????????????????????
?????????????????????????????????????????????????????
eradication evaluation. Thus, it is very important to 
make a follow-up appointment for increasing the post-
eradication evaluation rate. Additionally, UBT is the 
??????????????????????????H. pylori eradication, and 
the monoclonal stool antigen test (SAT) is a suitable 
alternative.11? ????????????????????????????????????????
be performed at least 4-8 weeks after the completion 
of H. pylori eradication therapy.11 
We performed a UBT at least 2 months after the 
completion of treatment to minimize the likelihood 
of false-negative results. However, it became more 
???????????????????????????????????????????????????????
initiation of H. pylori eradication therapy, and only 
Table 1. Patients’ backgrounds (n = 335)
Overall (a)
Post-eradication follow-up
(b)/(a)×100
(%)Complete (b) 
(n = 248)
Incomplete (c)  
(n = 87)
Age
??????????
< 48 years
176
159
142
106
34
53
80.7
66.7
Gender
Female
Male
125
210
103
145
22
65
82.4
69.0
Residential area
Aomori city
Others
291
44
219
29
72
15
75.3
65.9
Instructor
???????????????
Another gastroenterologist
173
162
129
119
44
43
74.6
73.5
Purpose of EGD
Asymptomatic on screening 173 115 58 66.5
Detailed examination 162 133 29 82.1
Presence of dyspepsia 101 78 23 77.2
Preventive measures for GC 61 55 6 90.2
After radiographic screening for GC 49 44 5 89.8
For the diagnosis of H. pylori infection 12 11 1 91.7
EGD: esophagogastroduodenoscopy; GC: gastric cancer
Table 2. ???????? ?????? ????????????????????????????????????????????????????????????????????????????????????? ?? ???????????????
?????????
Variables Crude OR (95% CI) p Adjusted OR (95% CI) p 
?????????????? 2.09 (1.27–3.44) 0.004 1.85 (1.11–3.09) 0.019
Female 2.10 (1.22–3.62) 0.008 1.89 (1.07–3.34) 0.027
Residing in Aomori city 1.57 (0.80–3.10) 0.190 1.36 (0.67–2.75) 0.390
?????????????????????????????? 1.06 (0.65–1.73) 0.817 1.01 (0.61–1.68) 0.971
Detailed examination
Presence of dyspepsia 1.28 (0.74–2.21) 0.381 1.46 (0.82–2.62) 0.198
Preventive measures for GC 3.85 (1.59–9.29) 0.003 4.01 (1.61–10.0) 0.003
??????????????????????????????????????????????????????????
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7.1% of the overall study population (29/411) received 
follow-up appointments in the present study. Although 
patients need to be cautious of the temperature for 
sample preservation and avoid the collection of a 
watery stool sample while performing the SAT, the 
provision of an SAT kit when introducing H. pylori 
eradication therapy might increase the motivation 
???? ?? ??????????????? ???????????????????? ??????? ???
the SAT is that the patients are not required to fast on 
the morning of the appointed day. In Japan, an SAT 
comprising an immunochromatographic assay (Rapid 
Testmate Pylori Antigen?, Wakamoto Pharmaceutical, 
????????????????? ???????????????????????????????????????
and the results can be rapidly obtained on the day of 
examination.12
The fact that not all patients are evaluated after 
receiving eradication therapy is a serious concern for 
both the medical care system and medical economy. 
??????????? ???????? ??? ????????????????? ??????????????
therapy leads to wasted medical expenditures related 
to diagnosis and treatment [i.e. > 10000 Japanese yen 
(JPY) or 91 US dollars (USD) per patient are wasted; 
1 USD = 110 JPY]. If H. pylori-associated diseases, 
including peptic ulcers and gastric cancer, occur in the 
failure group without follow-up, the amount of wasted 
medical expenditures is increased. Approximately 1.5 
million people per year are estimated to receive H. 
pylori eradication therapy in Japan; therefore, a large 
amount of the money spent on health insurance could 
be wasted.13 In addition, the annual reinfection rate 
after successful H. pylori eradication was reported 
to be 0.22–2.0% in Japan.14,15 If H. pylori infection 
is diagnosed in a patient who has not undergone 
post-eradication tests for H. pylori, it is impossible 
??? ???????????? ???????????? ??????????????? ????????????
????????????????? ????? ?????????? ???? ????????????H. 
pylori eradication therapies are approved by the 
???????????????????????????????????????????????????????
to select the appropriate therapeutic regimen in such 
cases.
??????????????????????????????????????????????????
48 years, female gender and preventive measures for 
gastric cancer were independently related to a higher 
rate of completion of post-eradication follow-up. 
The concern regarding post-treatment evaluation is 
relatively stronger among patients with any relevant 
factors, and the application of preventive measures for 
gastric cancer has the greatest impact on the completion 
of post-eradication evaluation. Particularly, of the 12 
patients who wished to be examined for H. pylori 
infection, 11 (91.7%) patients received post-treatment 
????????????? ??????? ???? ????? ??????? ?????????? ?????
the desire to be assessed for H. pylori infection most 
highly motivated patients to evaluate the results of 
their eradication therapy. Contrary to expectation, 
presence of dyspepsia was not a relevant factor; this 
may be because resolution of the symptom due to 
the treatment might have decreased the motivation 
for post-treatment follow-up. The Japanese Society 
for Helicobacter Research has stated that any ‘H. 
pylori infection’ is considered as the indication for 
eradication, irrespective of the background diseases.1 
In countries, such as Japan, with a high prevalence 
of H. pylori infection and gastric cancer, H. pylori 
eradication accompanied with active screening is 
recommended for young people. The importance 
of post-treatment evaluation, particularly among 
????????????????????????????? ????????????????????????
emphasized in a screening test.
The present study had several limitations. First, 
this was a single-center study. Second, the patients’ 
?????????? ???? ???????????? ?????? ????? ?????????? ????
completion of follow-up after H. pylori eradication 
therapy; however, these data were unavailable in the 
patients’ electronic medical records. Furthermore, 
statistical analyses after adjustment for numerous 
confounding factors, including the patients’ social and 
clinical characteristics, could not be conducted.
CONCLUSION
?????? ??? ??????? ??????? ??????? ???? ???????????
measures for gastric cancer were independently related 
to a higher rate of completion of post-eradication 
follow-up.
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